The role of surgery in recurrent ovarian cancer has been one of the more contested questions in gynaecological oncology over the last decade. The 2019 publication of the GOG-213 trial in NEJM challenged the historical assumption that secondary cytoreductive surgery improved outcomes in platinum-sensitive recurrent ovarian cancer. The trial found no survival benefit from adding surgery to chemotherapy in a broad population of recurrent patients.
A more nuanced picture has since emerged. The DESKTOP III trial (NEJM 2021), using strict patient selection criteria, found a meaningful survival benefit from secondary cytoreduction in carefully selected patients. The contemporary consensus has settled on the position that secondary cytoreductive surgery is a high-value intervention for selected patients, and that the discipline of patient selection determines whether the procedure helps or doesn’t.
This piece reviews the current evidence base, the selection framework, and the role of surgical complexity in determining outcomes.
The two trials in tension
GOG-213 (NEJM 2019) randomised patients with platinum-sensitive recurrent ovarian cancer to chemotherapy alone or chemotherapy + secondary cytoreductive surgery. The trial found no overall survival benefit and trended slightly toward worse outcomes in the surgical arm. Quality-of-life measures favoured the chemotherapy-only arm in the immediate post-operative period.
DESKTOP III (NEJM 2021) randomised a more strictly selected subset of patients, those with positive AGO score (good performance status, complete primary cytoreduction, no ascites > 500 mL), to chemotherapy alone or chemotherapy + secondary cytoreductive surgery. The trial found significant survival benefit in the surgical arm (median OS 53.7 months vs 46.0 months) and meaningful PFS extension.
The reconciliation: patient selection is everything. The same procedure performed in broadly-selected patients produces no benefit; performed in carefully-selected patients produces meaningful benefit.
The AGO score, the central selection tool
The AGO score for predicting cytoreduction feasibility in recurrent ovarian cancer consists of three criteria:
- Performance status ECOG 0
- Complete cytoreduction at the primary operation
- No ascites > 500 mL on imaging
Positive AGO score (all three present) predicts approximately 75% likelihood of complete (CC-0) secondary cytoreduction. Negative AGO score predicts much lower likelihood.
DESKTOP III selected patients with positive AGO score and demonstrated meaningful survival benefit in this subset. GOG-213 used broader inclusion criteria and demonstrated no overall benefit. The interpretation: in patients where complete cytoreduction is achievable, surgery helps; in patients where it isn’t, surgery doesn’t help and may cause harm.
For Indian practice, applying the AGO score before recommending secondary cytoreduction is now the appropriate standard.
Other selection considerations
Beyond the AGO score, additional factors that affect the surgical decision in recurrent ovarian cancer:
Platinum sensitivity. Patients with platinum-sensitive recurrence (disease-free interval > 6 months after first-line chemotherapy) benefit substantially more than platinum-resistant patients. Platinum-resistant recurrent disease is generally not a surgical candidate.
Disease distribution. Localised recurrence, a single peritoneal nodule or a single lymph node, is more amenable to surgical resection than multifocal disease. Imaging characterisation (CT, MRI, sometimes laparoscopy) is essential before committing to surgery.
Disease-free interval. Longer disease-free intervals correlate with better surgical outcomes. Patients with very short intervals (3–6 months) may not benefit from secondary cytoreduction even with otherwise favourable features.
Histology and molecular profile. High-grade serous, BRCA-mutated disease has distinct treatment trajectory. PARP inhibitor availability has changed the calculus for medical management, potentially reducing the marginal value of surgical resection in some scenarios.
Patient fitness and goals. Surgery is significant intervention. Patient performance status, comorbidity, and personal goals all influence the decision.
Surgical complexity and outcomes
A specific clinical question that has emerged: does surgical complexity matter for secondary cytoreduction outcomes, and if so, how?
Surgical complexity in cytoreductive surgery refers to the extent of organ resection required, number of resections, types of resections (bowel, splenectomy, peritonectomy, etc.), and overall procedure duration. Higher surgical complexity generally indicates more extensive disease and operating in more difficult anatomy.
The published Indian institutional analysis of the impact of surgical complexity on clinical outcomes in secondary cytoreductive surgery for recurrent ovarian cancer explores this question. Key observations:
- Surgical complexity is a marker for both disease burden and the operating team’s capability, interpretation requires distinguishing these
- Higher-complexity cases at experienced sub-speciality centres can still achieve CC-0, the volume-outcome relationship is real
- Complexity alone is not a contraindication, the question is whether the operating team can safely execute a complex operation, not whether complexity itself predicts failure
- Outcomes correlate with achieved CC-0 status more than with complexity per se, once cytoreduction is complete, the original complexity matters less than the residual disease status
What this means for practice
For Indian sub-speciality practice, several practical implications follow:
- AGO score should be a default pre-operative assessment in any patient being considered for secondary cytoreduction. Documentation of performance status, primary surgery completeness, and ascites volume from imaging is the baseline.
- Multidisciplinary tumour board review is essential. The surgery-versus-chemotherapy decision in recurrent disease benefits enormously from medical oncology, radiation oncology, and gynaecological oncology joint review. The decision is too consequential to be made by any single specialist.
- PARP inhibitor consideration must be part of the conversation. For BRCA-mutated or HRD-positive patients, the role of PARP inhibitors in maintenance therapy after first-line treatment has shifted the recurrent disease treatment landscape. Where PARP inhibitors are appropriate, the marginal value of surgical resection may be different from the calculation in non-PARP eligible patients.
- Surgical team experience is the variable that should drive case-by-case decision-making. The same patient may be a surgical candidate at one centre and not at another, based on the operating team’s ability to safely achieve CC-0 in the specific anatomical situation.
- Imaging characterisation should precede surgical commitment. Pre-operative imaging, particularly diffusion-weighted MRI and selective PET-CT, should clarify disease distribution. Laparoscopic exploration is reasonable in selected cases where imaging is ambiguous.
What patient counselling should include
For a patient being considered for secondary cytoreductive surgery for recurrent ovarian cancer, honest counselling should cover:
- The AGO score result for her specific case and the predicted likelihood of complete cytoreduction
- The realistic surgical outcomes, both the survival benefit (in DESKTOP III magnitude) and the risk of complications
- The alternative pathway of chemotherapy alone with or without PARP inhibitor maintenance
- The trajectory of recurrent ovarian cancer as a chronic disease with multiple lines of treatment available
- The patient’s own values about surgical intervention versus medical management
A patient who fully understands the AGO-stratified data and chooses surgery is in a different clinical situation than a patient who consents to surgery without that understanding.
The role of HIPEC in recurrent disease
A related question: in patients undergoing secondary cytoreductive surgery for recurrent ovarian cancer, should HIPEC be added?
The evidence here is less developed than for primary disease. The OVHIPEC-1 trial was specifically in primary Stage III disease at interval cytoreduction; extrapolating to recurrent disease requires caution. Several smaller trials and series have explored HIPEC in recurrent ovarian cancer with mixed results.
Current sub-speciality practice tends to consider HIPEC in recurrent disease for: – Patients with peritoneal-predominant recurrent disease – Patients undergoing comprehensive secondary cytoreduction with complete CC-0 achievable – Patients fit enough to tolerate the additional procedural intensity – Cases where the multidisciplinary tumour board specifically supports its addition
It is not routine in recurrent disease. The selection threshold is appropriately higher than for primary disease.
The bottom line
Secondary cytoreductive surgery for recurrent ovarian cancer is a high-value intervention for selected patients, specifically those with positive AGO score, platinum-sensitive recurrence, and the realistic prospect of complete cytoreduction by an experienced sub-speciality team. For these patients, DESKTOP III-magnitude survival benefit is the realistic expectation.
For broadly-selected patients, GOG-213 outcomes are the realistic expectation, no benefit, possibly slight harm. The discipline of selection is what determines which trial’s outcomes apply to any given patient.
For Indian sub-speciality practice, applying the AGO score, conducting tumour board review, and matching surgical complexity to team capability is the standard of care for this decision in 2026.
About the author
This piece was authored by Dr. Nishtha Tripathi Patel (MBBS, DGO, DNB, Fellowship in Gynaecological Oncology, ESGO-certified), an ESGO-certified gynaecological oncosurgeon in Ahmedabad with published academic work on surgical complexity and outcomes in secondary cytoreductive surgery for recurrent ovarian cancer. Reach the practice at +91 76988 00333.
Comments are closed.